New triple therapy shows promise for blood cancer patients
NCT ID NCT05943496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether combining three drugs (tafasitamab, acalabrutinib, and obinutuzumab) is safe and effective for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to control the cancer by targeting different pathways in cancer cells. About 27 adults will participate, and the study focuses on side effects and how well the treatment reduces cancer cells in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?